Literature DB >> 33478493

Risk assessment in precapillary pulmonary hypertension: a comparative analysis.

Thomas Sonnweber1, Eva-Maria Schneider1, Manfred Nairz1, Igor Theurl1, Günter Weiss1, Piotr Tymoszuk2, Judith Löffler-Ragg3.   

Abstract

BACKGROUND: Risk stratification is essential to assess mortality risk and guide treatment in patients with precapillary pulmonary hypertension (PH). We herein compared the accuracy of different currently used PH risk stratification tools and evaluated the significance of particular risk parameters.
METHODS: We conducted a retrospective longitudinal observational cohort study evaluating seven different risk assessment approaches according to the current PH guidelines. A comprehensive assessment including multi-parametric risk stratification was performed at baseline and 4 yearly follow-up time-points. Multi-step Cox hazard analysis was used to analyse and refine risk prediction.
RESULTS: Various available risk models effectively predicted mortality in patients with precapillary pulmonary hypertension. Right-heart catheter parameters were not essential for risk prediction. Contrary, non-invasive follow-up re-evaluations significantly improved the accuracy of risk estimations. A lack of accuracy of various risk models was found in the intermediate- and high-risk classes. For these patients, an additional evaluation step including assessment of age and right atrium area improved risk prediction significantly. DISCUSSION: Currently used abbreviated versions of the ESC/ERS risk assessment tool, as well as the REVEAL 2.0 and REVEAL Lite 2 based risk stratification, lack accuracy to predict mortality in intermediate- and high-risk precapillary pulmonary hypertension patients. An expanded non-invasive evaluation improves mortality risk prediction in these individuals.

Entities:  

Keywords:  Biomarkers; Cardiovascular disease; Mortality; Pulmonary hypertension; Risk assessment

Mesh:

Year:  2021        PMID: 33478493      PMCID: PMC7818775          DOI: 10.1186/s12931-021-01624-z

Source DB:  PubMed          Journal:  Respir Res        ISSN: 1465-9921


  25 in total

1.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.

Authors:  Marius M Hoeper; Tilmann Kramer; Zixuan Pan; Christina A Eichstaedt; Jens Spiesshoefer; Nicola Benjamin; Karen M Olsson; Katrin Meyer; Carmine Dario Vizza; Anton Vonk-Noordegraaf; Oliver Distler; Christian Opitz; J Simon R Gibbs; Marion Delcroix; H Ardeschir Ghofrani; Doerte Huscher; David Pittrow; Stephan Rosenkranz; Ekkehard Grünig
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2016-02

3.  The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.

Authors:  Raymond L Benza; Mardi Gomberg-Maitland; Dave P Miller; Adaani Frost; Robert P Frantz; Aimee J Foreman; David B Badesch; Michael D McGoon
Journal:  Chest       Date:  2011-06-16       Impact factor: 9.410

4.  The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.

Authors:  N Nickel; H Golpon; M Greer; L Knudsen; K Olsson; V Westerkamp; T Welte; M M Hoeper
Journal:  Eur Respir J       Date:  2011-09-01       Impact factor: 16.671

5.  Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort.

Authors:  James J Anderson; Edmund M Lau; Melanie Lavender; Raymond Benza; David S Celermajer; Nicholas Collins; Carolyn Corrigan; Nathan Dwyer; John Feenstra; Mark Horrigan; Dominic Keating; Fiona Kermeen; Eugene Kotlyar; Tanya McWilliams; Bronwen Rhodes; Peter Steele; Vivek Thakkar; Trevor Williams; Helen Whitford; Kenneth Whyte; Robert Weintraub; Jeremy P Wrobel; Anne Keogh; Geoff Strange
Journal:  Chest       Date:  2019-09-26       Impact factor: 9.410

6.  Risk assessment in pulmonary arterial hypertension.

Authors:  Marius M Hoeper; David Pittrow; Christian Opitz; J Simon R Gibbs; Stephan Rosenkranz; Ekkehard Grünig; Karen M Olsson; Doerte Huscher
Journal:  Eur Respir J       Date:  2018-03-29       Impact factor: 16.671

7.  Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension.

Authors:  François Haddad; Onno A Spruijt; Andre Y Denault; Olaf Mercier; Nathan Brunner; David Furman; Elie Fadel; Harm J Bogaard; Ingela Schnittger; Bojan Vrtovec; Joseph C Wu; Vinicio de Jesus Perez; Anton Vonk-Noordegraaf; Roham T Zamanian
Journal:  JACC Cardiovasc Imaging       Date:  2015-05-14

8.  A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension.

Authors:  David Kylhammar; Barbro Kjellström; Clara Hjalmarsson; Kjell Jansson; Magnus Nisell; Stefan Söderberg; Gerhard Wikström; Göran Rådegran
Journal:  Eur Heart J       Date:  2018-12-14       Impact factor: 29.983

9.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

10.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

View more
  2 in total

Review 1.  Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression.

Authors:  Shu-Hao Wu; Yih-Jer Wu
Journal:  Acta Cardiol Sin       Date:  2022-03       Impact factor: 2.672

2.  Short-Term Impact of Iron Deficiency in Different Subsets of Patients with Precapillary Pulmonary Hypertension from an Eastern European Pulmonary Hypertension Referral Center.

Authors:  Ioan Tilea; Dorina Nastasia Petra; Razvan Constantin Serban; Manuela Rozalia Gabor; Mariana Cornelia Tilinca; Leonard Azamfirei; Andreea Varga
Journal:  Int J Gen Med       Date:  2021-07-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.